Platelet membrane-camouflaged nanoparticles carry microRNA inhibitor against myocardial ischaemia‒reperfusion injury

Tianyi Wang, Tingting Zhou, Mingming Xu, Shuo Wang, Anqi Wu, Mingyang Zhang, You Lang Zhou, Jiahai ShiJournal of Nanobiotechnology 2022 · DOI

Abstract

The incidence of myocardial ischaemia‒reperfusion injury (MIRI) is increasing every year, and there is an urgent need to develop new therapeutic approaches. Nrf2 is thought to play a protective role during MIRI and it is regulated by microRNAs (miRNAs). This study focused on PLGA nanoparticles camouflaged by platelet membrane vesicles (PMVs) (i.e., PMVs@PLGA complexes) carrying microRNA inhibitors, which regulate Nrf2 and can play a therapeutic role in the MIRI process. In vitro and in vivo characterization showed that PMVs@PLGA has excellent transfection efficiency, low toxicity and good targeting. MicroRNAs that effectively regulate Nrf2 were identified, and then PMVs@PLGA-miRNA complexes were prepared and used for in vitro and in vivo treatment. PMVs@PLGA-miRNA complexes can effectively target the delivery of inhibitors to cardiomyocytes. Our results suggest that PMVs@PLGA complexes are a novel delivery system and a novel biological approach to the treatment of MIRI.

Introduction

When a patient suffers a myocardial infarction, the immediate clinical goal is reperfusion—restoring blood flow to oxygen-starved tissue. However, this restoration can trigger a secondary phenomenon known as Myocardial Ischaemia–Reperfusion Injury (MIRI). The sudden influx of oxygen generates a massive burst of reactive oxygen species (ROS) and inflammation, which can be as damaging as the initial blockage.

The protein Nrf2 serves as the body’s master regulator of antioxidant defenses, but its expression is often suppressed during MIRI by specific microRNAs (miRNAs). While miRNA inhibitors (antagomirs) could theoretically restore Nrf2 levels, they are hindered by rapid degradation in the bloodstream and a lack of heart-specific targeting. This study addresses these challenges using a biomimetic nanotechnology approach.

Design and Synthesis of the "Trojan Horse"

To overcome delivery barriers, researchers developed a multi-layered nanoparticle system termed PMVs@PLGA-miRNA. The system utilizes a stable PLGA (polylactic-glycolic acid) core modified with PEI (polyethyleneimine) to provide a positive charge for loading negatively charged miRNA inhibitors.

The defining feature of this system is the "cloak": Platelet Membrane Vesicles (PMVs) harvested from rats. Platelets naturally home to sites of vascular injury and inflammation, and their membranes are rich in targeting ligands such as CD31, CD41, and CD61. By fusing these membranes onto the PLGA nanoparticles using ultrasound, the researchers created a biomimetic delivery vehicle capable of evading the immune system and targeting injured heart tissue.

Schematic diagram of PMVs@PLGA-miRNA complexes for treating MIRI, illustrating synthesis, delivery, and the intracellular mechanism of action.

Characterization and Cellular Uptake

Physical characterization confirmed the successful coating of the PLGA core with platelet membranes. Transmission electron microscopy (TEM) revealed a core-shell structure, and dynamic light scattering showed a slight increase in diameter following membrane fusion, consistent with the addition of a lipid bilayer. Western blot analysis confirmed that the final complexes retained key platelet surface proteins (CD31, CD41, CD42b, and CD61), which are essential for their targeting capabilities.

Characterization and cellular uptake of PMVs@PLGA nanoparticles, including morphology, size distribution, protein marker analysis, and transfection efficiency.

In vitro studies using H9C2 cardiomyocytes demonstrated that the PMVs@PLGA system achieved over 85% transfection efficiency, significantly higher than bare nanoparticles. Furthermore, the system exhibited a sustained release profile, with approximately 80% of the miRNA cargo released over 21 days, providing a prolonged therapeutic window.

Therapeutic Efficacy in MIRI

The researchers identified miR-155-5p as the primary miRNA suppressing Nrf2 during MIRI. By delivering miR-155-5p inhibitors via the PMVs@PLGA system, they observed significant therapeutic benefits in a rat model of MIRI:

  • Cardiac Function Recovery: Treated rats showed significant improvements in Ejection Fraction (EF) and Fractional Shortening (FS).
  • Infarct Reduction: TTC staining revealed a dramatic reduction in the size of the myocardial infarction compared to untreated controls.
  • Biomarker Improvement: Clinical markers of heart damage, such as Troponin I (cTnI) and Myoglobin (MYO), were significantly reduced.
  • Molecular Protection: The treatment successfully upregulated Nrf2, increased antioxidant enzymes (SOD, GPx), and decreased pro-apoptotic markers like BAX.

Conclusion and Future Directions

This study validates the use of platelet-cloaked nanoparticles as a potent "Trojan Horse" for targeted cardiac therapy. By leveraging natural homing mechanisms, the PMVs@PLGA-miRNA system effectively delivers genetic cargo to injured cardiomyocytes, boosting the Nrf2 pathway and mitigating MIRI.

Future work will focus on long-term safety assessments beyond the 10-day window used in this study and exploring the scalability of the membrane-fusion manufacturing process. Additionally, the authors suggest that "hybrid" membranes—combining platelet and myocardial cell membranes—could further refine heart-specific targeting for clinical applications.

Summary updated

Abstract

The incidence of myocardial ischaemia‒reperfusion injury (MIRI) is increasing every year, and there is an urgent need to develop new therapeutic approaches. Nrf2 is thought to play a protective role during MIRI and it is regulated by microRNAs (miRNAs). This study focused on PLGA nanoparticles camouflaged by platelet membrane vesicles (PMVs) (i.e., PMVs@PLGA complexes) carrying microRNA inhibitors, which regulate Nrf2 and can play a therapeutic role in the MIRI process. In vitro and in vivo characterization showed that PMVs@PLGA has excellent transfection efficiency, low toxicity and good targeting. MicroRNAs that effectively regulate Nrf2 were identified, and then PMVs@PLGA-miRNA complexes were prepared and used for in vitro and in vivo treatment. PMVs@PLGA-miRNA complexes can effectively target the delivery of inhibitors to cardiomyocytes. Our results suggest that PMVs@PLGA complexes are a novel delivery system and a novel biological approach to the treatment of MIRI.
BibTeX
@article{wang2022platelet,
  author = {Tianyi Wang and Tingting Zhou and Mingming Xu and Shuo Wang and Anqi Wu and Mingyang Zhang and You Lang Zhou and Jiahai Shi},
  title = {{Platelet membrane-camouflaged nanoparticles carry microRNA inhibitor against myocardial ischaemia‒reperfusion injury}},
  journal = {Journal of Nanobiotechnology},
  year = {2022},
  doi = {10.1186/s12951-022-01639-8},
}
Figure